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Cardiac arrest (CA) remains a major cause of death and
severe disability worldwide. The ischemic process that
follows the cessation of cerebral perfusion and oxygena-
tion, which is further worsened by the reperfusion injury
occurring after the return of spontaneous circulation,
can lead to severe hypoxic brain damage, resulting in a
high rate of poor neurological recovery among CA
survivors.
The use of mild therapeutic hypothermia, or targeted
temperature management (TTM) as recently suggested
[1], has been recommended in CA patients since the pub-
lication of two randomized clinical trials in 2002, the
results of which demonstrated a significant improvement
in neurologically intact survival for comatose CA patients
presenting with ventricular fibrillation or ventricular
tachycardia [1,2]. Current guidelines suggest that mild
therapeutic hypothermia should also be considered in
patients presenting with other rhythms, although this has
been less well studied [3].
In experimental studies, TTM provided significant car-
diac and neurological protective effects through different
pathways. Hypothermic mechanisms providing myocar-
dial protection include, amongst all, improved energy
production during ischemia, increased calcium sensitivity
of myocytes, regulation of mitochondrial oxidative phos-
phorylation and preserved myocardial vascular autoregu-
lation [4,5]. All of these protective mechanisms would
result in increased myocardial contractility. After a post-
anoxic injury, TTM may also protect cerebral function
through reduced release of excitatory (that is, glutamate
and dopamine) neurotransmitters, attenuation of reactive
oxygen species production, preservation of the blood–
brain barrier, protection of cerebral microcirculation and
decrease in intracranial pressure [6,7]. As several path-
ways are involved in the pathogenesis of extended
post-anoxic brain damage, TTM can be considered as a
general and nonspecific neuroprotective strategy, which
may efficiently attenuate and mitigate most of these
mechanisms and potentially improve patients’ neurologi-
cal outcome. Interestingly, recent studies have underlined
not only that the hypothermic phase is important in this
process, but that strict control of the patient’s tempera-
ture during the first 3 days since hospital admission (that
is, rapid achievement of target temperature, a precise
control of temperature during the maintenance phase, a
slow and controlled rewarming and avoidance of fever
for 48 to 72 hours) are key components to enhance TTM
effectiveness after post-anoxic brain injury [8].
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